Pre-Open Stock Movers 04/06: (TUFN) (BTAI) (TLRY) Higher; (CANO) (CAR) (JBLU) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
BioXcel Therapeutics (BTAI) PT Raised to $84 at Canaccord Genuity
April 7, 2022 7:56 AM EDTCanaccord Genuity analyst Sumant Kulkarni raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $84.00 (from $81.00) while maintaining a Buy rating.
The analyst commented, "Earlier today (4/6), BTAI announced that the FDA approved Igalmi (BXCL501, dexmedetomidine film) for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. We had earlier characterized approval as a... More
BioXcel Therapeutics (BTAI) PT Raised to $76 at Jefferies
April 6, 2022 11:40 AM EDTJefferies analyst Chris Howerton raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $76.00 (from $73.00) while maintaining a Buy rating on FDA Approval of IGALMI Sublingual Film.
The analyst noted the label was broad, pricing is soon, and trade-launch in Q3.
... MoreTilray (TLRY) PT Raised to $8.40 at Cantor Fitzgerald
April 6, 2022 10:41 AM EDTCantor Fitzgerald analyst Pablo Zuanic raised the price target on Tilray (NASDAQ: TLRY) to $8.40 (from $6.90) while maintaining a Neutral rating following results and the recent re-rate higher on U.S. news flow.
The analyst commented, "We think the main takeaway from this... More
